Treating multiple myeloma in the UK

Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, talks on the treatment approaches used for patients with multiple myeloma in the UK. Typically, fit patients are treated with bortezomib-thalidomide-dexamethasone (VTD) induction prior to stem cell transplantation and lenalidomide maintenance. Upon relapse, treatment options are decided based on the patient’s treatment history. For patients who are transplant-ineligible, lenalidomide-based or bortezomib-based regimens are commonly used. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.